At the same time, the data imply that a medicinal chemistry campaign focusing on engineering pharmacokinetically optimized GLP-1–MK-801 conjugates might give rise to drugs that could outperform the current incretin-based treatments for obesity, such as semaglutide and tirzepatide. Here, GCG is linked to obesity disorder.